Correlation Between Mineralys Therapeutics, and Xilio Development

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Xilio Development at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Xilio Development into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Xilio Development, you can compare the effects of market volatilities on Mineralys Therapeutics, and Xilio Development and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Xilio Development. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Xilio Development.

Diversification Opportunities for Mineralys Therapeutics, and Xilio Development

0.41

Correlation Coefficient

Mineralys Therapeutics,  Xilio Development

Very weak diversification

The 3 months correlation between Mineralys and Xilio is 0.41. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Xilio Development in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xilio Development and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Xilio Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xilio Development has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Xilio Development go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Xilio Development

Given the investment horizon of 90 days Mineralys Therapeutics, is expected to generate 3.51 times less return on investment than Xilio Development. But when comparing it to its historical volatility, Mineralys Therapeutics, Common is 2.11 times less risky than Xilio Development. It trades about 0.04 of its potential returns per unit of risk. Xilio Development is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  86.00  in Xilio Development on August 30, 2024 and sell it today you would earn a total of  15.00  from holding Xilio Development or generate 17.44% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Xilio Development

Mineralys Therapeutics,

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Xilio Development

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Xilio Development are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Xilio Development displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Mineralys Therapeutics, and Xilio Development

The main advantage of trading using opposite Mineralys Therapeutics, and Xilio Development positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Xilio Development can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xilio Development will offset losses from the drop in Xilio Development's long position.

The idea behind Mineralys Therapeutics, Common and Xilio Development pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.